financetom
Business
financetom
/
Business
/
UK finance firms told to beef up buffers against CrowdStrike-like events
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
UK finance firms told to beef up buffers against CrowdStrike-like events
Oct 31, 2024 5:55 PM

LONDON (Reuters) - Financial companies in Britain must prepare to ensure they can deliver business services in "severe but plausible" scenarios, such as a global tech outage, to minimise any impact on consumers and markets, the markets regulator said on Thursday.

In a statement outlining what lessons could be learned after U.S. cybersecurity firm CrowdStrike's ( CRWD ) botched software update caused global chaos in July, the Financial Conduct Authority (FCA) said unregulated third-party problems were the leading cause of operational incidents reported between 2022 and 2023.

CrowdStrike's ( CRWD ) popular core technology, the Falcon platform, detects and responds to malicious threats. But an outage on July 19 led to worldwide flight cancellations and hit industries including banks, healthcare, media companies and hotel chains.

The FCA, which checked in with firms over the incident to understand its impact, said consumer harm had been minimal. However, it said companies had until March 2025 to ensure they could withstand such events.

It called on companies to consider a series of steps, including ensuring that testing scenarios were adequate, improving third-party risk controls and ensuring contracts clearly set out responsibilities for service monitoring, incident notification and updates during and after incidents.

"We encourage all firms, regardless of how they were affected by the CrowdStrike ( CRWD ) incident, to consider these lessons, to improve their ability to respond to and recover from future disruptions," the FCA said.

(Reporting by Kirstin Ridley; Editing by Emelia Sithole-Matarise)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Kontoor Brands Insider Sold Shares Worth $1,825,095, According to a Recent SEC Filing
Kontoor Brands Insider Sold Shares Worth $1,825,095, According to a Recent SEC Filing
Jun 3, 2024
03:57 AM EDT, 06/03/2024 (MT Newswires) -- Scott H Baxter, Director, Chair, President and Chief Executive Officer, on May 30, 2024, sold 25,332 shares in Kontoor Brands ( KTB ) for $1,825,095. Following the Form 4 filing with the SEC, Baxter has control over a total of 477,257 shares of the company, with 318,188 shares held directly and 159,069 controlled...
Ideaya Biosciences Insider Sold Shares Worth $1,032,884, According to a Recent SEC Filing
Ideaya Biosciences Insider Sold Shares Worth $1,032,884, According to a Recent SEC Filing
Jun 3, 2024
03:56 AM EDT, 06/03/2024 (MT Newswires) -- Michael Anthony White, Chief Scientific Officer, on May 29, 2024, sold 28,500 shares in Ideaya Biosciences ( IDYA ) for $1,032,884. SEC Filing: https://www.sec.gov/Archives/edgar/data/1676725/000161071724000272/xslF345X03/form4.xml ...
ACM Research Insider Sold Shares Worth $1,947,356, According to a Recent SEC Filing
ACM Research Insider Sold Shares Worth $1,947,356, According to a Recent SEC Filing
Jun 3, 2024
03:53 AM EDT, 06/03/2024 (MT Newswires) -- David H Wang, 10% Owner, Director, Chief Executive Officer, President, on May 29, 2024, sold 86,090 shares in ACM Research ( ACMR ) for $1,947,356. Following the Form 4 filing with the SEC, Wang has control over a total of 1,449,858 shares of the company, with 504,018 shares held directly and 945,840 controlled...
AstraZeneca Says Potential Breast Cancer Treatment Reduces Risk of Disease Progression by up to 38%
AstraZeneca Says Potential Breast Cancer Treatment Reduces Risk of Disease Progression by up to 38%
Jun 3, 2024
03:53 AM EDT, 06/03/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Sunday that a phase 3 trial of Enhertu showed statistically significant and clinically meaningful improvement in treating certain types of metastatic breast cancer over chemotherapy. The patients included those with HR-positive, HER2-low metastatic breast cancer as well as the overall trial population of patients with HR-positive, HER2-low and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved